Functional analysis of IL-11 in chalangiocarcinoma and its clinical application

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K09204
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55020:Digestive surgery-related
• Research Institution: Hyogo Medical University
• Principal Investigator: Uyama Naoki 兵庫医科大学, 医学部, 非常勤講師 (70402873)
• Co-Investigator(Kenkyū-buntansha): 末岡 英明 兵庫医科大学, 医学部, 講師 (20419831) ; 須藤 誠 兵庫医科大学, 医学部, ポストドクター (40415427) ; 藤元 治朗 兵庫医科大学, 医学部, 特別招聘教授 (90199373) ; 波多野 悦朗 兵庫医科大学, 医学部, 非常勤講師 (80359801) ; 岡本 共弘 兵庫医科大学, 医学部, 助教 (00567208)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: 肝内胆管癌 / IL-11 / gp130 / 増殖能

Outline of Final Research Achievements

Thre kinds of antibodies used to evaluate the reactivity for IL-11 in the human ICC tissues. Reactiviry of these antibodies was different and significant relationship between IL-11 reactivity and patient prognosis was not found. In human ICC cell lines, expression of IL-11 receptor complex, IL-11Ra and gp130, was found. IL-11 significantly was significantly involved in the proliferlation of all ICC cell lines. However, in matrigel invasion assay, IL-11 was not involved in the ability of invasion in all ICC cell lines. IL-11 may be involved in the proliferation of ICC.

Free Research Field

肝内胆管癌

Academic Significance and Societal Importance of the Research Achievements

組織レベルではIL-11の明らかな予後への関与が認められなかったが、細胞レベルでは、IL-11はICCの増殖能に関与している可能性が示された。今後ICCの治療にIL-11の活性を抑制する薬剤やIL-11シグナルを抑制するような薬剤が見つかれば、増殖能が抑制される可能性があると考えられた。